Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 3, 1996, Pages 585-591

  Pisansky, Thomas M ^a   Blute, Michael L ^b   Suman, Vera J ^a   Bostwick, David G ^a   Earle, John D ^a   Zincke, Horst ^b  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

Grade; Neoplasm staging; Prostate cancer; Prostate specific antigen bl (blood); Prostatectomy; Prostatic neoplasms pa (pathology); Seminal vesicles pa (pathology); Stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

EID: 0030272187     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00359-8     Document Type: Article

References (38)

1. 1. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia: J.B. Lippincott; 1992.
2. 2. Bostwick, D. G. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am. J. Surg. Pathol. 18:796-803; 1994.
3. 3. Bostwick, D. G.; Myers, R. P.; Oesterling, J. E. Staging of prostate cancer. Semin. Surg. Oncol. 10:60-72; 1994.
4. 4. Catalona, W. J.; Smith, D. S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 152:1837-1842; 1994.
5. 5. Chelsky, M. J.; Schnall, M. D.; Seidmon, E. J.; Pollack, H. M. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J. Urol. 150:391-395; 1993.
6. 6. Corn, B. W.; Hanks, G. E.; Schultheiss, T. E.; Hunt, M. A.; Lee, W. R.; Coia, L. R. Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 32:325-330; 1995.
7. 7. D'Amico, A. V.; Whittington, R.; Malkowicz, S. B.; Schnall, M.; Tomaszewski, J.; Schultz, D.; Kao, G.; Vanarsdalen, K.; Wein, A. A multivariable analysis of clinical factors predicting for pathologic features associated with local failure after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 30:293-302; 1994.
8. 8. Diaz, A.; Roach, M.; Marquez, C.; Coleman, L.; Pickett, B.; Wolfe, J. S.; Carroll, P.; Narayan, P. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 30:323-329; 1994.
9. 9. Ennis, R. D.; Flynn, S. D.; Fischer, D. B.; Peschel, R. E. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer. Implications for the choice of primary treatment. Int. J. Radiat. Oncol. Biol. Phys. 30:317-322; 1994.
10. 10. Epstein, J. I.; Pizov, G.; Walsh, P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582-3593; 1993.
11. 11. Ferguson, J. K.; Bostwick, D. G.; Suman, V.; Zincke, H.; Oesterling, J. E. Prostate-specific antigen detected prostate cancer - Pathologic characteristics of ultrasound visible vs. ultrasound invisible tumors. Eur. Urol. 27:8-12; 1995.
12. 12. Gleason, D. F. Histologic grading of prostatic carcinoma. In: Bostwick, D. G., ed. Pathology of the prostate. New York: Churchill Livingstone; 1990:83-93.
13. 13. Klee, G. G.; Dodge, L. A.; Zincke, H.; Oesterling, J. E. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J. Urol. 151:94-98; 1994.
14. 14. Kleer, E.; Larson-Keller, J. J.; Zincke, H.; Oesterling, J. E. Ability of preoperative prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology 41:207-216; 1993.
15. 15. Lee, W. R.; Hanks, G. E.; Schultheiss, T. E.; Corn, B. W.; Hunt, M. A. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13:464-469; 1995.
16. 16. Marks, L. B.; Anscher, M. S. Radiotherapy for prostate cancer: Should the seminal vesicles be considered target? Int. J. Radiat. Oncol. Biol. Phys. 24:435-440; 1992.
17. 17. Mettlin, C.; Jones, G. W.; Murphy, G. P. Trends in prostate cancer care in the United States, 1974-1990: Observations from the patient care evaluations studies of the American College of Surgeons Commission on Cancer. CA Cancer J. Clin. 43:83-91; 1993.
18. 18. Mettlin, C.; Murphy, G. P.; Lee, F.; Littrup, P. J.; Chesley, A.; Babaian, R.; Badalament, R.; Kane, R. A.; Mostofi, F. K.; Mcauley, C.; Church, P.; Burgers, J.; Toi, A.; Gilbaugh, J. H. Characteristics of prostate cancer detected in the American Cancer Society National Prostate Cancer Detection Project. J. Urol. 152:1737-1740; 1994.
19. 19. Murphy, G. P.; Mettlin, C.; Menck, H.; Winchester, D. P.; Davidson, A. M. National patterns of prostate cancer treatment by radical prostatectomy - Results of a survey by the American College of Surgeons Commission on Cancer. J. Urol. 152:1817-1819; 1994.
20. 20. Myers, R. P.; Fleming, T. R. Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 4:461-472; 1983.
21. 21. Oesterling, J. E.; Jacobsen, S. J.; Chute, C. G.; Guess, H. A.; Girman, C. J.; Panser, L. A.; Lieber, M. M. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270:860-864; 1993.
22. 22. Ohori, M.; Scardino, P. T.; Lapin, S. L.; Seale-Hawkins, C.; Link, J.; Wheeler, T. M. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am. J. Surg. Pathol. 17:1252-1261; 1993.
23. 23. Ohori, M.; Wheeler, T. M.; Scardino, P. T. The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer 74:104-114; 1994.
24. 24. Partin, A. W.; Yoo, J.; Carter, H. B.; Pearson, J. D.; Chan, D. W.; Epstein, J. I.; Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J. Urol. 150:110-114; 1993.
25. 25. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, E. D.; Kozelsky, T. F.; Wieand, H. S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
26. 26. Platt, J. F.; Bree, R. L.; Schwab, R. E. The accuracy of CT in the staging of carcinoma of the prostate. AJR 149:315-318; 1987.
27. 27. Potosky, A. L.; Miller, B. A.; Albertsen, P. C.; Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548-552; 1995.
28. 28. Rifkin, M. D.; Zerhouni, E. A.; Gatsonis, C. A.; Quint, L. E.; Paushter, D. M.; Epstein, J. I.; Hamper, U.; Walsh, P. C.; McNeil, B. J. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N. Engl. J. Med. 323:621-626; 1990.
29. 29. Roach, M.; Marquez, C.; Yuo, H. S.; Narayan, P.; Coleman, L.; Nseyo, U. O.; Navvab, Z.; Carroll, P. R. Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28:33-37; 1994.
30. 30. Smith, D. S.; Catalona, W. J. The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol. 152:1732-1736; 1994.
31. 31. Stone, N. N.; Stock, R. G.; Unger, P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J. Urol. 154:1392-1396; 1995.
32. 32. Tempany, C. M.; Zhou, X.; Zerhouni, E. A.; Rifkin, M. D.; Quint, L. E.; Piccoli, C. W.; Ellis, J. H.; McNeil, B. J. Staging of prostate cancer - Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 192:47-54; 1994.
33. 33. Terris, M. K.; McNeal, J. E.; Freiha, F. S.; Stamey, T. A. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J. Urol. 149:1035-1039; 1993.
34. 34. Trapasso, J. G.; deKernion, J. B.; Smith, R. B.; Dorey, F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 152:1821-1825; 1994.
35. 35. Vallancien, G.; Bochereau, G.; Wetzel, O.; Bretheau, D.; Prapotnich, D.; Bougaran, J. Influence of preoperative positive seminal vesicle biopsy on the staging of prostatic cancer. J. Urol. 152:1152-1156; 1994.
36. 36. Villers, A. A.; McNeal, J. E.; Redwine, E. A.; Freiha, F. S.; Stamey, T. A. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J. Urol. 143:1183-1187; 1990.
37. 37. Zietman, A. L.; Coen, J. J.; Shipley, W. U.; Althausen, A. F. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from PSA failure. Urology 42:292-298; 1993.
38. 38. Zincke, H.; Oesterling, J. E.; Blute, M. L.; Bergstralh, E. J.; Myers, R. P.; Barrett, D. M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 152:1850-1857; 1994.